The characteristics of mesenchymal stromal cells (MSCs) which derived from multiple myeloma (MM) patients are typically impaired in osteogenic differentiation. However, the underlying molecular mechanisms need to be further investigated. lncRNAs are emerging as critical regulation molecules in oncogenic pathways. In this study, we identified that bioactive lncRNA HOXC-AS3, which is transcribed in opposite to HOXC10, was presented in MSCs derived from bone marrow (BM) of MM patients (MM-MSCs). HOXC-AS3 was able to interact with HOXC10 at the overlapping parts and this interaction increased HOXC10 stability, then promoted its expression, conferring osteogenesis repression to MM-MSCs. In mouse models, intravenously administered siHOXC-AS3 was proven to be effective in prevention of bone loss, sustained by both anticatabolic activities and bone-forming. These data showed that lncHOXC-AS3 was required for osteogenesis in BM-MSCs by enhancing HOXC10 expression. Our finding thus unveils a novel insight for the potential clinical significance of lncRNA HOXC-AS3 as a therapeutic target for bone disease in MM. STEM CELLS 2019;37:247-256
INTRODUCTION
Multiple myeloma (MM) is a hematologic malignant characterized by abnormal proliferation of neoplastic plasma cells within the bone marrow (BM). The imbalance in bone remodeling in MM patients results in bone lesions, which is one of the clinical features of MM [1, 2] . Understanding the underlying regulatory mechanisms and developing effective therapeutic strategies against bone disease are greatly desired in the clinical practice.
The homeobox gene HOXC10 participates in the cell replication and tissue regeneration [3, 4] . Knockdown of HOXC10 enhances cell growth, inhibits apoptosis, and increases cell motility in breast cancers [5] . In glioma cells, HOXC10 plays an important role in controlling the cell proliferation and invasive capacities, as well as regulating immunosuppressive gene expression [6] . Mesenchymal stem cells are multidirectional differentiation potential cells [7] . According to the International Society for Cellular Therapy criteria, mesenchymal stromal cells (MSCs) derived from BM which consist of a subset of stem cells are presently acting as putative mesenchymal stem cells for therapeutic aim [8, 9] . Many findings, including our previous work, have indicated that MSCs were related to osteogenesis and became a potential therapeutic target for bone disease in MM [1, 10, 11] . Up to now, the specific role of HOXC10 in MSCs derived from MM remains poorly understood.
A large proportion of the mammalian genomes is transcribed to lncRNAs, which play critical roles in various biological processes [12] [13] [14] [15] . In cancers, lncRNAs have been identified as critical regulatory a Department of Haematology, The Second Affiliated Hospital of Soochow University, Suzhou, People's Republic of China; b Department of Cell molecules in oncogenic pathways [13, [16] [17] [18] . Recent genomics and transcriptomic researches highligted that abundant protein coding transcripts have their bioactive antisense transcript partners, most of which are lncRNAs [14, 19] . The antisense lncRNAs play a key role in regulating the expression of their associated protein-coding genes [20] [21] [22] .
Our findings demonstrated that HOXC10 and its antisense transcript partner lncHOXC-AS3 had crucial function on the osteogenesis of MSCs derived from MM. We explored that overexpression of lncHOXC-AS3 could repress osteogenesis of MM-MSCs through targeting HOXC10 transcription. Moreover, the results suggested that HOXC-AS3, a natural antisense lncRNA, can bind to HOXC-AS3, thereby increasing its stability by reducing its decay. Our data provided a novel protein coding sense/noncoding antisense transcripts approach to improve the transcriptional regulation programs. In addition, we highlight the superiority of using this distinctive RNA as a valuable target for clinical therapeutic interference in bone lesions in MM.
MATERIALS AND METHODS

Cell Lines
U266, a human myeloma cell line was cultured in RPMI-1640 Medium (HyClone, Logan, UT) supplemented with 10% fetal bovine serum. Cell line authentication was performed by cell line characterization core using short tandem repeat profiling (Genetic Testing Biotechnology Corporation, Suzhou, China).
Patients and Subjects
This study involved seven health volunteers and eight MM patients with newly diagnosed MM (Supporting Information Table S1 ). All subjects were provided by the Second Affiliated Hospital of Soochow University in accordance with the institutional guidelines. The informed consent, which was obtained according to the procedures approved by the Ethics Committee of the Affiliated Hospital of Soochow University was signed by all the volunteers.
Isolation and culture of BM-derived MSCs were performed as described previously [10, 11, [23] [24] [25] . MM-MSCs1 to MM-MSCs6 which correspond to those from MM patient #1 to patient #6, respectively, were used in this study.
RNA Isolation and RT-PCR, qRT-PCR Analysis
Total RNA was extracted from cell lines using TRIzol™ Reagent (Invitrogen, Carlsbad, CA). For mRNA expression analysis, the first-strand cDNA was generated using the Reverse Transcription System Kit (Thermo Fisher Scientific) with random primers or Oligo dT. Quantitative real-time PCR was performed on triplicate samples in a reaction mix of SYBR Green (Promega, Madison, WI) with ABI 7500 StepOne Plus Real-Time PCR System (Applied BioSystems, Foster City, CA).
Plasmids Construction
Full-length cDNA (HOXC10) was subcloned into the Lenti-CMVpuro vector.
Osteogenic Differentiation Assay
The culture-expanded cells, 2 × 10 4 per cm 2 , were grown under osteogenic induction conditions, which consists of the growth medium supplemented with 10% Fetal Calf Serum (FCS), 7.0 × 10 −3 mol/L β-glycerolphosphate, 2.0 × 10 −4 mol/L ascorbicacid, and 1.0 × 10 −8 mol/L dexamethasone. Media was replaced every 3 days during 2 weeks. This time point was considered as day 0. Fresh osteogenic induction medium was added every 2 days for 14 days to maintain the activity of cells.
Alizarin Red and Von Kossa Staining
Alizarin red and von Kossa staining were performed to evaluate mineral deposition at 14 days after osteogenic induction. Cells were washed with cold phosphate-buffered saline (PBS) and prepared by fixation in 10% formalin for 1 hour. After washing with deionized water, cells were treated with 2% silver nitrate at 37 C in the dark for 30 minutes. Then cells were exposed to room light for 1-2 hours until the stained are as turned dark. After 2 weeks, for alizarin red staining, the cells were collected and fixed with 70% ice-cold alcohol at −20 C for 1 hour, and stained for 10 minutes with alizarin red (40 Mm, pH 4.2, Solarbio).
U266-Luc Cell Line Generation
To obtain cell lines stably expressing luciferase and Green Fluorescent Protein (GFP), recombinant lentiviruses containing luciferase and GFP (PHBLV-CMV-MCS-EF1-ZsGreen-T2A-fLUC) were purchased from HANBIO (Shanghai, China). U266 were transfected lentiviruses according to the instruction and dualluciferase reporter assays were performed. The relative luciferase activities were assessed with Dual Luciferase Reporter Assay System (Promega) following product manual after 24 hours transfection.
Cell Transfection
Electroporation of siRNAs into cells was carried by the Neon Transfection system (Invitrogen). Briefly, siRNA and appropriate amount of cells were added into a sterile, 1.5 ml microcentrifuge tube and gently mix. Fill the Neon Tube with 3 ml Electrolytic Buffer and insert it into the Neon Pipette Station, then aspirate the mixture into Neon Tip electroporated at 990 V, 40 ms, 1 pulse.
siRNAs
The siRNAs specially targeting HOXC-AS3 or HOXC10 and nontarget negative control siRNA were purchased from Gene-Pharma Co. Ltd. (Shanghai, China). Vivo-grade siRNAs would be promising siRNA delivery systems for in vivo tumor-targeted therapy [26] [27] [28] . SiRNA sequences were listed in Supporting Information Table S3 .
Stability and α-Amanitin Treatment
MSCs were cultured in typical growth medium, and then transfected with 20 μM siRNA using Neon electroporation system (Invitrogen). 20 nM of α-amanitin was added to medium. Cells were harvested for RNA isolation and qPCR at 6, 12, and 24 hours post-treatment. Results were representative of three independent experiments. 18s RNA was used as internal control.
In Vivo Xenograft Studies
We established the MM models in accordance with the institutional guidelines for the use of experimental animals, after acquiring permission from the local Ethical Committee. Fourweek-old female NOD-Prkdcscid Il2rgtm1/Bcgen (NSG) mice were provided by Biocytogen Company (Beijing, China). Before tumor cell inoculation, mice were acclimated for 1 week. A total ©AlphaMed Press 2018 STEM CELLS of 1 × 10 6 luciferase-labeled U266 cells were transplanted via the lateral tail vein. When the sizes of xenografts were matched, five mice were intravenously injected with carfilzomib (8 mg/kg) and vivo-grade HOXC-AS3 siRNA (1.5 mg/kg), and five mice with carfilzomib and scrambled siRNA, twice a week for 4 weeks.
After giving the mice 75 mg/kg of D-luciferin (Promega), we imaged mice with IVIS Lumina II optical imaging system (Caliper Life Sciences, Hopkinton, MA). Serial bioluminescence imaging was used for envaluating tumor burden. The Living Images software was performed to quantify bioluminescence.
Microcomputed Tomography Analysis
The SkyScan 1,172 micro-computed tomography (CT) scanner (SkyScan, Aartselaar, Belgium) was used to analyze bones (9-mm voxel size, 59 KVp, 127 mA, 0.48 rotation step). Image acquisition and data analyses were performed using the Conebeam CT Reconstruction Software (version 2.6). The following trabecular parameters were analyzed: bone volume (BV)/total volume, connectivity, and trabecular separation (Tb. Sp).
Markers of Bone Turnover in Mouse Serum Analysis
N-terminal propeptide of type I procollagen (P1NP; indicating bone formation) and Carboxy-terminal telopeptide of type 1 collagen (CTX; indicating bone resorption) in mice sera were analyzed by Enzyme-Linked Immunosorbent Assay (ELISA) (Enzyme-linked Biotechnology Co., Ltd., Shanghai, China).
Gene Expression Omnibus Dataset Analysis
Analysis of expression profiles was obtained from the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/; accession no. GSE80608). MSCs in this study were cultured in RPMI1640 medium with 10% fetal bovine serum [29] .
RNA Fluorescence In Situ Hybridization and Immunofluorescence Microscopy
Fluorescent probes of HOXC-AS3 for RNA Fluorescence In Situ Hybridization (FISH) were designed and produced by RIBO BIO (China). In brief, MSCs were fixed with 10% paraformaldehyde for 10 minutes, and then MSCs were incubated with special RNA probe. 4 0 ,6-diamidino-2-phenylindole (DAPI) (1:5,000) in PBS was used to stain nucleus. Confocal microscopy (LSM 710, Carl Zeiss, Jena, Germany) was used to observe the localization of HOXC-AS3 in MSCs.
Gene Set Enrichment Analysis
The Java implementation of Gene Set Enrichment Analysis (GSEA) software (version 3.0) [30] was used to analyze the differentiation gene sets. The data processing method were provided by Broad Institute GSEA website (www.broad.mit.edu/ gsea). The different expressions of gene sets in MM-MSCs versus ND-MSCs were defined by GSEA.
Cell Nucleus/Cytoplasm Fraction Isolation
Cytoplasmic and nuclear fractions were isolated and purified using the Nuclear/Cytosol Fractionation Kit (BioVision incorporated). Cells were collected and washed with PBS, then cytosolic extraction buffer was added, after 15 minutes incubation on ice. Cells were collected by scraping and centrifuged at 16,000 rpm at 4 C for 5 minutes. The cytosol supernatants were collected and nuclear pellets were resuspended in nuclear extraction buffer, followed by incubation for 40 minutes on ice with occasional vortexing. Nuclear proteins were centrifuged at 16,000 rpm at 4 C for 10 minutes and the supernatants were collected. Cytoplasmic and nuclear RNA were isolated as described previously.
Rapid Amplification of cDNA Ends Assay 5 0 -Rapid amplification of cDNA ends (RACE) and 3 0 -RACE analyses were performed to determine the transcriptional initiation and termination sites of HOXC-AS3 using a 5 0 RACE System for Rapid Amplification of cDNA Ends (Invitrogen). The PCR of the RACE analysis was performed by gene-specific primers which were listed in Supporting Information Table S2 .
Northern Blotting
All the experiments were done according to DIG Northern Starter Kit (Roche Diagnostics, Basel, Switzerland). The total RNA was extracted from MSCs by standard TRIZOL methods, followed by electrophoresis with 1.5% formaldehyde agarose gel. The samples were transferred to Biodyne Nylon membrane (Pall, NY) using 20× SSC buffer (pH 7.0, 3.0 M NaCl, and 0.3 M sodium citrate). After ultraviolet crosslinking, membrane was treated with hybrid buffer for 30 minutes prehybridization, followed by treatment with DIG-labeled RNA probes generated by in vitro transcription at 68 C for 12 hours. DIG signals were detected according to the introduction of chemiluminescent.
RNase Protection Assay
The total RNA was extracted using 1 ml of TRIZOL reagent (Invitrogen), RNase A (Tiangen, China) was used to treat RNA samples. Then, single stranded RNAs were digested but not double stranded RNAs. Before treatment with an RNase A, the RNA samples were incubated at 37 C for 60 minutes, followed by incubation at 37 C for 30 minutes after addition of the RNase A. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) were performed to examine the formation by primers within the overlapping region or nonoverlapping regions following the RNase Protection Assay.
Statistical Analysis
R (version 3.3.2) was used for all the statistical analyses in this study. Data were showed as mean AE SD. Two-tailed Student's t test was performed to assess the diversity of mean values between two groups. The correlation between the expressions of HOXC10 and HOXC-AS3 was analyzed by Pearson correlation analysis. p values less than .05 were considered to be significant.
RESULTS
Upregulation of HOXC10 Promoted Contributed to Osteogenic Differentiation Repression of MM-MSCs
To investigate the mechanism of osteogenic differentiation in MSCs from MM, gene expression profiling of MSCs derived from MM patients (MM-MSCs) and those from normal donors (ND-MSCs) were analyzed using GEO database (GSE80608). The GSEA analysis indicated that the upregulation of osteogenic differentiation signatures (the gene sets: GO_REGULATION_ OF_OSTEOBLAST_DIFFERENTIATION and GO_POSITIVE_REGU-LATION_OF_OSTEOBLAST_DIFFERENTIATION) were strongly correlated with ND-MSCs (Fig. 1A) . The GSEA analysis suggested that the osteogenesis potential of MSCs was impaired www.StemCells.com ©AlphaMed Press 2018
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in MM patients and resulted in osteoblast deficiency. The heatmaps showed that the most differentially expressed genes between MM-MSCs and ND-MSCs (logFC > 1; p > .05; Fig. 1B ). QPCR data further confirmed the top 19 genes in ND-MSCs (n = 7) and MM-MSCs (n = 8). Among the top 19 genes, 6 genes which were validated in the above analysis were subjected to the loss-of-function analysis in MM-MSCs1 and MM-MSCs2 by RNAi. Notably, we found that downregulation of HOXC10 increased osteogenic differentiation of MM-MSCs (Fig. 1C, 1D , Supporting Information Fig. S1A ). Moreover, markers of osteogenic differentiation, osteopontin, and osterix, were upregulated in siHOXC10-MM-MSCs compared with siControl-MM-MSCs at day 14 in osteogenic medium (Fig. 1E , Supporting Information Fig. S1B ). In concordance with loss-of-function studies, when HOXC10 expression was upregulated in ND-MSCs, osteogenic potential of MSCs was repressed (Supporting Information Fig. S1C-S1E ). HOXC10 expression was significantly upregulated in MM-MSCs compared with that in ND-MSCs (logFC = 1.65, p = .0005; GSE80608; Fig. 1F ). In good accord with the previously published data [29] , our clinical data showed that the HOXC10 mRNA levels were upregulated in MM-MSCs relative to those from ND (Fig. 1G ). Taken together, these results suggested that upregulation of HOXC10 in MSCs contributed to reduction of osteogenic capacity.
LncRNA HOXC-AS3 Interacted with HOXC10 and Increased its Stability
Antisense transcripts may regulate alternative splicing, transport or structural stability of the sense transcripts by forming double stranded RNA structures with its sense transcript [20] . HOXC10 and HOXC-AS3 genes are positioned at chromosome 12q13.13 and transcribed in opposite directions. They are overlapped and formed a 5 0 head-to-head pairing pattern. HOXC-AS3 initiates in the HOXC10 exon 1 and overlaps HOXC10 exon 1 with 44 nucleotides (Graphical Abstract). RNase protection assay was performed on RNA from MSCs to investigate the possibility of RNA interaction between HOXC10 and HOXC-AS3. RNase A was used to digest single-stranded RNA and the residual duplex structure was detected using qPCR assay by primers which related to different parts of HOXC10 and HOXC-AS3 transcripts ( Fig. 2A) . These results suggested that the overlapping region of both transcripts was protected from degradation, indicating that there indeed existed an interaction between HOXC10 and HOXC-AS3 ( Fig. 2A , Supporting Information Fig. S2A ). RNA-RNA interaction could modify the secondary or tertiary structure of RNA, protect RNA from RNase degradation and thereby increase its stability [31, 32] . To investigate whether the overlapping HOXC10 and HOXC-AS3 interaction affect the stability of HOXC10, we assessed the stability of HOXC10 transcripts by blocking new RNA synthesis with α-amanitin (an RNA polymerase II inhibitor) and measuring the loss of HOXC10, GAPDH, and 18s RNA over a 24 hours period (Fig. 2B ). We found that the half-life of HOXC10 was much shorter in HOXC-AS3 siRNA cells than in control siRNA cells upon transcriptional inhibition by α-amanitin (Fig. 2C , Supporting Information Fig. S2B ), indicating that HOXC10 was decaying more rapidly in the former. This finding suggested that knockdown HOXC-AS3 resulted in a decreased stability of HOXC10. Collectively, the data demonstrated that HOXC-AS3 formed an RNA interaction with HOXC10, which led to enhance the stability of HOXC10 by reducing its decay.
Characterization of lncRNA HOXC-AS3
In order to identify the biologic function of lncRNA HOXC-AS3 and consider the possible significance in MSCs, we characterized HOXC-AS3. Lysates were prepared from nuclear and cytoplasmic fractions and examined by qPCR, in accord with qPCR data, RNA FISH indicated that HOXC-A3 was presented in both the cytoplasm and nucleus. (Fig. 3A, 3B ). Rapid amplification of cDNA ends (RACE) were performed to identify the sequence of 5 0 and 3 0 ends and one splice variant 368 nt was identified (Fig. 3C ). We found a poly-A tail, indicating that HOXC-AS3 is a fully processed transcript of RNA polymerase II. Coding Potential Assessment Tool (http://lilab.research.bcm.edu/cpat/) [33] analysis displayed that HOXC-AS3 had no coding potentiality (Supporting Information Table S4 ). Northern blotting was performed to further confirm the presence of full length HOXC-AS3 in MSCs1 and MSCs2 (Fig. 3D ). Altogether, these results showed that HOXC-AS3 was a classic transcript longer than 200 nucleotides with limited protein coding potential.
HOXC-AS3 Decreased Osteogenic Potential of MSCs by Regulating HOXC10 Expression
The antisense transcripts regulate the expression of sense transcripts in general [34] . We investigated whether the HOXC-AS3 transcript regulated expression of HOXC10 mRNA. We transiently downregulated HOXC-AS3 in MM-MSCs by siRNA. We found that the downregulation of HOXC-AS3 significantly reduced the HOXC10 expression in MM-MSCs (Fig. 4A, 4B) .
To further explore the relationship between HOXC-AS3 and HOXC10 in MSCs, the correlation of the HOXC10/HOXC-AS3 pairs was assessed using Pearson correlation analysis. The fact that a significant positive correlation between HOXC10 and HOXC-AS3 was observed indicated that the positive correlation of the sense/antisense pairs existed in both MM-MSCs and ND-MSCs (r = .688, p = .005, Fig. 4C ). Next, we explored whether HOXC-AS3 was involved in regulating osteogenesis in MSCs. HOXC-AS3 mRNA level was upregulated in MSCs derived from MM relative to those from ND (Fig. 4D) . Moreover, downregulation of HOXC-AS3 increased osteogenic differentiation of MM-MSCs (Fig. 4E, 4F , Supporting Information Fig. S3A,  S3B) . Together, HOXC-AS3 enhanced HOXC10 expression, thus led to repressing osteogenic potential of MSCs.
Targeting HOXC-AS3 Enhanced Osteogenic Potential In Vivo
We next used "human-in-mouse" Xeno-transplantation MM models to evaluate the effect of HOXC-AS3 on osteogenic differentiation in vivo. Bioluminescent MM models (U266-luc) were established, which included the clinical symptoms, such as the anatomic morphology of bone lesions and the hallmark of bone pathophysiology present in myeloma patients [35] (Fig. 5A) . The human myeloma cell line U266 was generated to stably express firefly luciferase, as well as a selectable marker, GFP. Xeno-transplantation MM models were established by intravenous injection of luciferase-expressing U266 cells. After injection of luciferin, tumor burden was evaluated by serial whole body noninvasive imaging of visible light given off by U266-luc cells. Bioluminescent imaging revealed that HOXC-AS3 siRNA treatment had little impact on remission of tumor burden as assessed by the noninvasive bioluminescence imaging (Fig. 5A, 5B) .
Mouse MSCs from the BM of mice were isolated using previously described method [25] . HOXC-AS1 expression in the mouse MSCs was performed by qPCR to confirm the injected siRNA efficiency in vivo (Fig. 5C ). To investigate the development of bone loss in the mouse models, trabecular and cortical bone were assessed by microCT. Typical microCT images at the distal femurs indicated obvious bone loss in the vehicle control group and the control vivo-grade siRNA-treated mice, compared with trabecular structures detected in HOXC-AS3 
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vivo-grade siRNA-treated mice (Fig. 5D ). Bone morphometric showed dramatically significant decrease in Tb. Sp and increase in trabecular BV and connectivity in HOXC-AS3 siRNA-treated group, as compared with the vehicle control or the siRNA control (Fig. 5E, 5G) ). Moreover, these results were relevant to bone turnover markers levels analyzed in serum after HOXC-AS3 siRNA treatment. CTX, a bone resorption marker was significantly decreased in HOXC-AS3 siRNA group (Fig. 5H) . The bone formation marker, P1NP, increased significantly in the HOXC-AS3 siRNA mice compared with the control mice ( Fig. 5I ). Along with our in vitro data, these evidences obviously suggested that HOXC-AS3 repressed osteogenic differentiation of MSCs and downregulation of HOXC-AS3 had an effect on preventing bone lesions.
DISCUSSION
MSCs in BM are the haemopoietic-supporting stroma components of the marrow and the progenitor cells of osteoblasts, which play a critical role in the formation and function of the BM microenvironment [7, 36] . Many findings, including our previous work, have indicated that the suppression of osteogenesis potential in MSCs results in osteoblast deficiency in MM patients [1, 10, 11] . To further elucidate mechanisms of osteogenesis repression in MM-MSCs, we retrieved a database containing gene expression profile of MSCs derived from MM and those derived from ND (GSE80608). The analysis of this dataset showed that the expression of HOXC10 in MM-MSCs were upregulated in MM-MSCs. Moreover, our results suggested that high expression of HOXC10 in MM-MSCs contributed to decreased osteogenic potential.
LncRNAs are momentous regulators in cellular processes including cell proliferation apoptosis and cell cycle [18, 37, 38] . LncRNAs accomplish their functions by various mechanisms such as scaffolding cellular complex regulating the gene expression and coupling with DNA or RNAs. Protein-coding mRNAs have natural antisense transcript partners most of which are noncoding RNAs [14, 19] . Natural antisense lncRNA transcripts have vital functions in regulating their sense gene expression and could set up a novel clinical therapeutics target [22, 39, 40] . In this study we identified a natural antisense transcript HOXC-AS3 arises from intergenic regions of the HOXC10 gene. Our data showed that as a pair of protein-coding sense/ noncoding antisense transcripts HOXC-AS3 bound to HOXC10 thereby increasing its stability by reducing its decay. And by enhancing the stability of HOXC10 HOXC-AS3 upregulated the HOXC10 expression. In addition downregulation of HOXC-AS3 decreased HOXC10 expression thus subsequently increasing osteogenic potential in MSCs. Importantly therapeutic HOXC-AS3 siRNA was effective on ameliorating bone lesions in MM models suggesting the vital role of lncHOXC-AS3 in MSCs.
We and others have implicated that there existed two types of regulation between sense and antisense RNA [32, 41, 42] . In the discordant regulation, the antisense RNAs inhibited the sense RNAs. In contrast, the antisense transcripts enhanced the expression of the sense transcripts in the concordant regulation. In this research, a sense/antisense pair was characterized, which was increased synchronously and correlated positively in MM-MSCs. Our data provided an evidence that a sense-antisense pair could decrease mRNA degradation at the post-transcription level by forming an RNA interaction at their complementary regions.
In conclusion, we presented the results suggested that disturbance of the antisense lncRNA HOXC-AS3 could affect the expression of its sense transcript HOXC10, indicating that antisense transcript HOXC-AS3 contributed to control of HOXC10 transcription in MSCs. These findings suggested that RNA-RNA direct interactions might be a common approach used by lncRNAs, and thus expansively mapping these interactions may Micro-computerized tomography (microCT) analysis of femora from the vehicle control group, the control siRNA-treated group and the HOXC-AS3 siRNA-treated group. Representative microCT images at the metaphyses of distal femurs show loss of trabecular architecture in the vehicle control group, the control siRNA-treated mice, but not in mice treated with HOXC-AS3 siRNA. Upper panel: two-dimensional images. Down panel: three-dimensional reconstruction images. Bone parameters of trabecular bone volume (E), connectivity (F) and trabecular bone separation (G) were shown. HOXC-AS3 siRNA significantly changed bone turnover markers in serum, increasing levels of P1NP (H), a bone formation marker, decreasing levels of CTX (I), a bone resorption marker, as compared with vehicle-treated mice. Graphs, mean AE SD. **, p < .01, ***, p < .001 versus vehicle control.
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CONCLUSION
In summary, we identified that bioactive lncRNA HOXC-AS3 which was transcribed from the antisense strand of HOXC10, was upregulated in MSCs isolated from myeloma patients. And lncHOXC-AS3 overexpression could repress osteogenesis of MM-MSCs by regulating HOXC10 transcription. Our study provided evidence that lncRNA HOXC-AS3 was novel therapeutic target and clinically relevant for bone disease in myeloma patients.
